Company also announces that the IMPACT-1 clinical trial is underway with open-label results expected in the coming months NEW YORK, Sept. 21, 2023 /PRNewswire/ — Transcend Therapeutics, a biotechnology company developing rapid-acting treatments for neuropsychiatric diseases, announced receipt of a collaborative grant award with Yale University to support first-of-its-kind preclinical research on…
